Last reviewed · How we verify
no NSAID
This drug targets the SGLT2 receptor to reduce glucose reabsorption in the kidneys.
This drug targets the SGLT2 receptor to reduce glucose reabsorption in the kidneys. Used for Type 2 diabetes, Heart failure.
At a glance
| Generic name | no NSAID |
|---|---|
| Sponsor | University Hospital, Strasbourg, France |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, the drug increases glucose excretion in the urine, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. The drug's effect on glucose levels is rapid and sustained, making it an effective treatment option.
Approved indications
- Type 2 diabetes
- Heart failure
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Hypotension
- Increased urination
Key clinical trials
- Association of Erectile Dysfunction With Neuropathic Pain, Disease Activity, and Functional Status in Male Patients With Axial Spondyloarthritis: A Cross-Sectional Observational Study
- Helping Osteoarthritis Patients to Walk With NSAID (PHASE4)
- Effects of Photobiomodulation and Topical Diclofenac on Inflammation and Pain in Knee Osteoarthritis (EPIC-KO) (PHASE2)
- Low-Dose Short-Term Ketorolac to Reduce Chronic Opioid Use in Orthopaedic Polytrauma Patients (PHASE4)
- Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery (PHASE4)
- Evaluating Suzetrigine for Pain Control Following TKA (PHASE3)
- Optimizing Proton Pump Inhibitors (PPI) Prescribing With EHR-Based Decision Support (NA)
- Prophylactic Sphincterotomy in Acute Biliary Pancreatitis Patients Unfit for Surgery (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |